Syndax Q2 Loss Widens to $60.2M Amid Rising SG&A

TL;DR

**SNDX's Q2 loss widened, signaling continued cash burn and a long road to profitability for this biotech.**

AI Summary

Syndax Pharmaceuticals Inc. reported a net loss of $60.2 million for the three months ended June 30, 2025, compared to a net loss of $55.1 million for the same period in 2024, representing a 9.3% increase in loss. For the six months ended June 30, 2025, the net loss was $118.9 million, up from $108.5 million in the prior year, an increase of 9.6%. Research and development expenses were $49.5 million for the three months ended June 30, 2025, a decrease from $50.3 million in the prior year, while selling, general, and administrative expenses increased to $12.8 million from $10.1 million. The company recognized collaboration revenue of $1.0 million for the three months ended June 30, 2025, a decrease from $1.2 million in the prior year. Strategic outlook includes continued investment in biopharmaceutical cancer therapeutics, with Axatilimab-related costs being a significant component of R&D. The company's cash and cash equivalents stood at $350.5 million as of June 30, 2025, providing liquidity for ongoing operations and clinical trials.

Why It Matters

Syndax's widening net loss and increased SG&A expenses signal continued high burn rates for investors, despite a slight dip in R&D. This financial performance is critical for investors assessing the company's runway and the timeline to profitability, especially in the highly competitive biopharmaceutical cancer therapeutics market. Employees might face pressure to deliver clinical milestones efficiently, while customers await the successful development and commercialization of new treatments like Axatilimab. The broader market will watch how Syndax manages its cash position of $350.5 million to fund its pipeline against larger, more established competitors.

Risk Assessment

Risk Level: high — The company reported a net loss of $60.2 million for Q2 2025 and $118.9 million for the six months ended June 30, 2025, indicating significant ongoing operational losses. This, coupled with a decrease in collaboration revenue from $1.2 million to $1.0 million year-over-year for Q2, highlights a reliance on existing capital for funding operations and drug development, posing a high financial risk.

Analyst Insight

Investors should closely monitor Syndax's cash burn rate and upcoming clinical trial milestones for Axatilimab. Given the widening losses and high R&D expenses, a cautious approach is warranted, and potential investors should assess the company's ability to secure additional funding or achieve significant clinical breakthroughs to offset current losses.

Financial Highlights

debt To Equity

Not Disclosed

revenue

$1.0M

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

-$60.2M

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

$350.5M

revenue Growth

-16.7%

Revenue Breakdown

Key Numbers

• $60.2M — Net Loss (Q2 2025) (Increased from $55.1M in Q2 2024, indicating widening losses.)
• $118.9M — Net Loss (YTD June 2025) (Increased from $108.5M in YTD June 2024, showing a sustained increase in losses.)
• $49.5M — R&D Expenses (Q2 2025) (Slight decrease from $50.3M in Q2 2024, but still a major expense.)
• $12.8M — SG&A Expenses (Q2 2025) (Increased from $10.1M in Q2 2024, contributing to higher operating costs.)
• $1.0M — Collaboration Revenue (Q2 2025) (Decreased from $1.2M in Q2 2024, indicating reduced external funding.)
• $350.5M — Cash and Cash Equivalents (June 30, 2025) (Provides liquidity for ongoing operations and clinical trials.)
• 9.3% — Increase in Q2 Net Loss (Percentage increase in net loss from Q2 2024 to Q2 2025.)
• 9.6% — Increase in YTD Net Loss (Percentage increase in net loss from YTD June 2024 to YTD June 2025.)

Key Players & Entities

• Syndax Pharmaceuticals Inc. (company) — filer of the 10-Q
• UCB Biopharma (company) — partner in a license agreement from July 2016
• Vitae Pharmaceuticals Inc. (company) — involved in an Allergan License Agreement from October 2017
• Allergan (company) — party to a license agreement with Vitae Pharmaceuticals Inc.
• Axatilimab (product) — key biopharmaceutical cancer therapeutic in development
• $60.2 million (dollar_amount) — net loss for Q2 2025
• $55.1 million (dollar_amount) — net loss for Q2 2024
• $118.9 million (dollar_amount) — net loss for the six months ended June 30, 2025
• $49.5 million (dollar_amount) — research and development expenses for Q2 2025
• $350.5 million (dollar_amount) — cash and cash equivalents as of June 30, 2025

FAQ

Risk Factors

• Increasing Net Losses [high — financial]: The company reported a net loss of $60.2 million for Q2 2025, an increase of 9.3% from $55.1 million in Q2 2024. Year-to-date losses also increased by 9.6% to $118.9 million. This trend indicates a continued burn rate that may require future financing.
• High R&D Investment [high — operational]: Research and development expenses were $49.5 million for Q2 2025. While a slight decrease from $50.3 million in Q2 2024, these costs remain substantial and are critical for pipeline development, particularly for Axatilimab.
• Rising SG&A Expenses [medium — operational]: Selling, general, and administrative expenses increased to $12.8 million in Q2 2025 from $10.1 million in Q2 2024. This 26.7% increase contributes to the overall widening net loss and may reflect increased operational or commercialization efforts.
• Clinical Trial and Regulatory Hurdles [high — regulatory]: As a biopharmaceutical company, Syndax is subject to extensive regulatory review and approval processes for its drug candidates. Delays or failures in clinical trials, such as those involving Axatilimab, can significantly impact development timelines and financial performance.
• Dependence on Future Financing [high — financial]: With significant ongoing R&D expenses and increasing net losses, the company's ability to continue operations is dependent on its cash reserves of $350.5 million and its capacity to secure additional funding through equity or debt offerings.

Industry Context

Syndax operates in the highly competitive biopharmaceutical sector, focusing on developing novel cancer therapeutics. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory oversight. Success hinges on innovation, clinical trial outcomes, and strategic partnerships.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Syndax faces significant regulatory risks. The development and approval of its drug candidates, particularly Axatilimab, are subject to rigorous review by agencies like the FDA. Any delays or setbacks in clinical trials or regulatory submissions could materially impact the company's future.

What Investors Should Do

1. Monitor R&D spend and clinical trial progress for Axatilimab.
2. Assess the sustainability of the current cash burn rate.
3. Evaluate the impact of rising SG&A expenses.

Glossary

Axatilimab

A drug candidate developed by Syndax Pharmaceuticals, likely a key focus of their research and development efforts in biopharmaceutical cancer therapeutics. (It represents a significant investment and a major component of the company's R&D expenses, indicating its strategic importance.)

Collaboration Revenue

Revenue generated from partnerships or agreements with other companies, often involving licensing of intellectual property or co-development of drugs. (A decrease in this revenue stream suggests potential shifts in partnership dynamics or milestone achievements.)

R&D Expenses

Costs incurred by the company for research and development activities, crucial for discovering and bringing new drugs to market. (These are the largest expense category for Syndax, reflecting their commitment to innovation in cancer therapeutics.)

SG&A Expenses

Selling, General, and Administrative expenses, which include costs related to marketing, sales, and the overall management of the company. (An increase in SG&A can indicate expansion of operations or increased efforts in commercialization activities.)

Year-Over-Year Comparison

Syndax Pharmaceuticals Inc. reported a widening net loss in the second quarter of 2025, with a loss of $60.2 million compared to $55.1 million in the prior year's quarter, a 9.3% increase. While R&D expenses saw a slight decrease, SG&A expenses rose by 26.7% to $12.8 million, contributing to the increased loss. Collaboration revenue also declined by 16.7% to $1.0 million. The company maintains a substantial cash position of $350.5 million, providing liquidity, but the overall trend indicates increased operational costs and a growing deficit.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on August 4, 2025 regarding Syndax Pharmaceuticals Inc (SNDX).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR